When it comes to CLL/SLL treatment, what’s the difference between BTK inhibitors and BCL-2 inhibitors? Understanding how these treatment approaches work and how they fit into the treatment…
BTK degrader BGB-16673 reduced tumor burden in 85% of patients from a high-risk, hard-to-treat group with relapsed / refractory CLL. Dr. Stephan Stilgenbauer from Ulm University and colleagues…
More than 2700 people lost their lives during the terrorist attacks on the World Trade Center in New York City. The attack also exposed hundreds of thousands of…
NEW YORK (Reuters Health) – Adding the anti-VEGF monoclonal antibody bevacizumab to FOLFOX chemotherapy does not improve outcomes in patients with stage II-III colon cancer, according to a…
ZURICH (Reuters) – Swiss pharma group Roche’s drug Perjeta (pertuzumab) significantly extended the lives of women with HER2-positive breast cancer compared to a placebo, according to new data…
NEW YORK (Reuters Health) – Compared to conventional cytology, liquid-based cytology is more than twice as sensitive in detecting cervical intraepithelial neoplasia (CIN) grade 2 or higher, without…
NEW YORK (Reuters Health) – After focal treatment of a limited number of brain metastases, whole-brain radiotherapy (WBRT) appears to have a negative impact on health-related quality of…
Mary Hesdorffer, NP and Executive Director of the Mesothelioma Applied Research Foundation, discusses the latest advances in treatment options for mesothelioma. Results from early-stage clinical trials show a…
NEW YORK (Reuters Health) – Sorafenib delivered concurrently with transarterial chemoembolization (TACE) is safe in patients with intermediate hepatocellular cancer and does not lead to any unexpected adverse…
NEW YORK (Reuters Health) – As second-line treatment for locally advanced or metastatic non-small-cell lung cancer in Chinese patients, pemetrexed is as effective as docetaxel but with fewer…
NEW YORK (Reuters Health) – Parenteral hydration offers virtually no benefit to hospice patients with advanced cancer. There are no established standards for hydration at the end of…
NEW YORK (Reuters Health) – While oxybutynin is often used prophylactically to reduce irritative urinary symptoms related to intravesical bacillus Calmette-Guerin (BCG) therapy for bladder cancer, it actually…
